- Home
- CLDI vs ADIL Comparison
CLDI vs ADIL Comparison
Compare CLDI & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- ADIL
- Stock Information
- Founded
- CLDI 2014
- ADIL 2010
- Country
- CLDI United States
- ADIL United States
- Employees
- CLDI N/A
- ADIL N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- ADIL Health Care
- Exchange
- CLDI Nasdaq
- ADIL Nasdaq
- Market Cap
- CLDI 8.7M
- ADIL 7.7M
- IPO Year
- CLDI N/A
- ADIL 2018
- Fundamental
- Price
- CLDI $1.58
- ADIL $0.36
- Analyst Decision
- CLDI
- ADIL Strong Buy
- Analyst Count
- CLDI 0
- ADIL 2
- Target Price
- CLDI N/A
- ADIL $4.75
- AVG Volume (30 Days)
- CLDI 161.6K
- ADIL 753.8K
- Earning Date
- CLDI 11-11-2025
- ADIL 11-12-2025
- Dividend Yield
- CLDI N/A
- ADIL N/A
- EPS Growth
- CLDI N/A
- ADIL N/A
- EPS
- CLDI N/A
- ADIL N/A
- Revenue
- CLDI N/A
- ADIL N/A
- Revenue This Year
- CLDI N/A
- ADIL N/A
- Revenue Next Year
- CLDI N/A
- ADIL N/A
- P/E Ratio
- CLDI N/A
- ADIL N/A
- Revenue Growth
- CLDI N/A
- ADIL N/A
- 52 Week Low
- CLDI $1.41
- ADIL $0.22
- 52 Week High
- CLDI $46.68
- ADIL $1.30
- Technical
- Relative Strength Index (RSI)
- CLDI 44.14
- ADIL 45.25
- Support Level
- CLDI $1.51
- ADIL $0.34
- Resistance Level
- CLDI $1.74
- ADIL $0.41
- Average True Range (ATR)
- CLDI 0.10
- ADIL 0.03
- MACD
- CLDI 0.04
- ADIL -0.00
- Stochastic Oscillator
- CLDI 30.43
- ADIL 27.51
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.